Mesenchymal stem cells and their secreted molecules predominantly ameliorate fulminant hepatic failure and chronic liver fibrosis in mice respectively by unknown
Huang et al. J Transl Med  (2016) 14:45 
DOI 10.1186/s12967-016-0792-1
RESEARCH
Mesenchymal stem cells and their 
secreted molecules predominantly ameliorate 
fulminant hepatic failure and chronic liver 
fibrosis in mice respectively
Biao Huang1†, Xixi Cheng1†, Huafeng Wang1,2†, Wenjing Huang1, Zha la Ga hu3, Dan Wang1, Kai Zhang1, 
Huan Zhang1, Zhenyi Xue1, Yurong Da1, Ning Zhang1, Yongcheng Hu4, Zhi Yao1, Liang Qiao5, Fei Gao6* 
and Rongxin Zhang1*
Abstract 
Background: Orthotopic liver transplantation is the only effective treatment for liver failure but limited with shortage 
of available donor organs. Recent studies show promising results of mesenchymal stem cells (MSCs)-based therapies.
Methods: We systematically investigate the therapeutic effects of MSCs or MSC-conditioned medium (MSC-CM) in 
ameliorating fulminant hepatic failure (FHF) and chronic liver fibrosis in mice. In addition, extensive flow cytometry 
analysis of spleens from vehicle and MSC- and MSC-CM-treated mice was applied to reveal the alteration of inflamma-
tory state.
Results: In FHF model, MSCs treatment reduced remarkably the death incidents; the analysis of gross histopathology 
showed that control livers were soft and shrunken with extensive extravasated blood, which was gradually reduced 
at later time points, while MSC–treated livers showed gross pathological changes, even 24 h after MSC infusion, and 
hematoxylin and eosin staining revealed dramatical hepatocellular death with cytoplasmic vacuolization suppressed 
by MSCs treatment; flow cytometry analysis of total lymphocytes showed that macrophages (F4/80) infiltrated into 
control livers more than MSC-treated livers; by contrast, MSC-CM partially ameliorates FHF. In chronic liver injury 
model, MSC and MSC-CM both suppressed fibrogenesis and necroinflammatory, and the later was better; activation 
of hepatic stellate cells (α-SMA) was inhibited; glycogen synthesis and storage (indicated by periodic acid-Schiff -stain-
ing) was improved; liver regeneration (Ki67) was promoted while liver apoptosis (TUNEL) was reduced. In the in vitro, 
MSCs promote macrophage line RAW264.7 apoptosis and MSC-CM promotes apoptosis and inhibits proliferation of 
HSC line LX-2. We also found that MSCs and MSC-CM could improve spleen; MSC-CM increased levels of Th2 and Treg 
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Background
For most animals, the liver is the most important meta-
bolic organ, and end-stage liver failure is a potentially 
life-threatening state that is frequently accompanied by 
severe complications. Liver failure includes FHF and 
chronic liver fibrosis, which can further deteriorate into 
cirrhosis and hepatoma. Orthotopic liver transplanta-
tion is currently the most effective treatment, but its use 
is limited due to a shortage of available donor organs, 
high costs, and requirements for life-long immunosup-
pression [1, 2]. Therefore, recent studies have focused 
on the therapeutic effects of different types of stem cells, 
which can improve liver function via distinct mecha-
nisms [3, 4].
MSCs, a specific type of adult stem cell isolated from 
compact bone, can differentiate into multi-lineage cells 
[5]. Moreover, MSCs naturally support homeostasis by 
secreting soluble factors, including trophic molecules 
and cytokines, which indirectly regulate the immune sys-
tem [6]. Recent studies show that MSCs down-regulate 
pro-inflammatory cells via different mechanisms in auto-
immune diseases [7, 8]. That is, different MSC therapies 
can alleviate the negative outcomes of injury and diseases 
via either interactions between MSC and various target 
cells [9–11] or MSC-secreted soluble factors [12]. How-
ever, differences between MSC therapies for liver failure 
have not been fully explored.
In the present study, we systematically studied the 
effects of MSCs and MSC-CM containing various MSC-
secreted soluble factors on FHF and chronic liver fibrosis 
in mice, focusing on CD4+ T lymphocytes, macrophages, 
and hepatic stellate cells (HSCs), which play important 
roles in the pathogenesis of liver failure. We showed that 
both MSC and MSC-CM treatment improved recovery 
from liver failure, although there were differences in their 
modes of action. That is, MSCs ameliorated FHF by inter-
acting with various inflammation-relevant cells, thereby 
achieving immunosuppression and promoting survival, 
whereas MSC-CM ameliorated chronic liver fibrosis by 




Two-to-three-week-old female ICR mice and six-to-
eight-week-old female ICR or C57BL/6 mice weighing 
20-25  g were purchased from the Laboratory Animal 
Center, Academy of Military Medical Sciences (Bei-
jing, China) and were housed in conventional cages. All 
experiments in this study were performed in accordance 
with the Academy of Military Medical Sciences Guide for 
Laboratory Animals.
Isolation and culture of bone‑derived MSCs
MSCs from murine compact bone were isolated and 
culture-expanded as described in previous report [13]. 
Phenotype and multipotent stem cell characteristics of 
infused MSCs were analyzed (Additional file  1: Figure 
S1). The details are placed in Additional file 1.
Preparation of MSC‑CM
Conditioned growth medium was concentrated 25-fold 
through ultrafiltration units (Millipore, Bedford, MA) 
with a 3-kDa cutoff [14]. The details are placed in Addi-
tional file 1.
Animal model and treatment protocols
The details are placed in Additional file 1.
Induction of FHF
FHF was induced by a single dose of thioacetamide (TAA; 
dissolved into 40  μg/μl with sterile PBS) injected intra-
peritoneally. After 5 h of TAA injection, 200 μl MSC-CM 
or 1 × 106 MSCs and 200 μl PBS solution (vehicle con-
trol) was infused into the tail vein.
Induction of chronic liver fibrosis
To induce liver fibrosis, mice received 12 consecutive 
intraperitoneal injections (1  μl/g body weight) of CCl4: 
olive oil (1:1) twice per week for 6 weeks. 1 × 106 MSCs 
were infused into the tail vein, or 200 μl MSC-CM were 
infused into tail vein twice per week for three consecutive 
weeks at the sixth week of CCl4 injections.
cells, and reduced levels of Th17 cells, whereas levels of Th1 cells were unchanged; comparatively, MSC treatment did 
not affect Th17 and Treg cells and only slightly alters inflammatory state; MSC and MSC-CM treatment both substan-
tially down-regulated macrophages in the spleens.
Conclusion: Both MSCs and MSC-CM exert therapeutic effects by acting on various key cells during the pathogen-
esis of FHF and chronic fibrosis, stimulating hepatocyte proliferation and suppressing apoptosis, down-regulating infil-
trating macrophages, converting CD4+ T lymphocyte system into an anti-inflammatory state, and facilitating hepatic 
stellate cell death.
Keywords: Liver failure, MSC-CM, Hepatic stellate cells, Macrophages, CD4+ T cells
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Immunohistochemistry
Various immunohistochemistry staining are performed 
as described in previous report [14]. The details are 
placed in Additional file 1.
Statistical analysis
Results are expressed as the mean ± standard deviation. 
Statistical significance was determined by a two-tailed 
Student t test. Survival was analyzed using the Kaplan–
Meyer product limit estimate and compared with the log-
rank test.
Results
MSCs improve gross and microscopic liver histopathology 
and prolong survival of mice with FHF
Mice were sacrificed 24, 48, and 72 h after MSCs intrave-
nous infusion (Additional file 1: Figure S2A). Nine control 
and one MSC-treated mouse died before sacrifice. Six of 
the nine remaining control livers were soft and shrunken 
with extensive extravasated blood, which was gradu-
ally reduced at later time points. By contrast, none of the 
remaining six MSC–treated livers showed gross patholog-
ical changes, even 24 h after MSC infusion (Fig. 1a).
Hematoxylin and eosin (HE)-stained liver sections 
from control mice revealed dramatical hepatocellu-
lar death with cytoplasmic vacuolization, panlobular 
mononuclear CD45-positive leukocyte infiltration (par-
ticularly F4/80-positive macrophages), and severe dis-
tortion of liver tissue architecture. By contrast, liver 
sections from MSC–treated mice rarely showed peripor-
tal immune cell infiltration with edema and fibrin depo-
sition (Fig. 1d–f; Additional file 1: Figure S2C–E). Also, 
flow cytometry analysis of total lymphocytes showed 
that macrophages infiltrated into control livers more 
than MSC-treated livers (Fig. 1c; Additional file 1: Figure 
S2B).
During the 7-day follow-up period after cell trans-
plantation, nine of the 18 control mice successively died, 
with mortality rate reaching 50  %. By contrast, bet-
ter survival was observed for MSC–treated mice, with 
only one mouse dying during the observation period 
(Fig. 1b).
Overall, these results demonstrate that MSC inhib-
its the development of histopathological changes and 
immune cell infiltration and reduces mortality among 
mice with TAA-induced FHF.
Fig. 1 MSC infusion promotes survival, improves gross and microscopic histopathology in TAA-induced FHF. a MSC treatment substantially 
improved the gross histopathological appearance of TAA-stimulated livers with reduction of extravasated blood. Asterisk marks the changes 
occurred to liver 24 h after MSC infusion. b Kaplan–Meier survival analysis of mice with TAA-induced FHF. c Flow cytometry analysis of macrophages. 
d HE staining e F4/80 immunohistochemistry f CD45+ immunofluorescence staining of livers sections from control and MSC-treated mice demon-
strated a massive reduction of leukocyte and macrophage infiltration. Data are shown as mean ± standard error of the mean of 10 random high-
power fields per mouse. *P < 0.05; **P < 0.01; ***P < 0.001
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MSC therapy suppresses CCl4‑induced chronic liver fibrosis 
and down‑regulates infiltrating macrophages
In order to observe changes in liver fibrosis after mice 
were treated with CCl4 and MSC, liver sections (Addi-
tional file  1: Figure S3) were stained with Sirius Red 
to identify collagen deposition. Six mice from normal, 
control and MSC groups were sacrificed for various 
microscopic evaluations 3  weeks after MSC infusion 
(Additional file  1: Figure S4A). Sirius Red-stained liver 
sections revealed massive collagen deposition in liv-
ers from control mice (Fig.  2a, f ). MSC treatment also 
noticeably decreased collagen deposition in mice with 
TAA-induced chronic liver fibrosis, although this effect 
was less significant than that observed in mice with CCl4-
induced chronic liver fibrosis (Additional file  1: Figure 
S3). The results of immunofluoresence staining of Col-
lagen1 (Col-1) and Collagen3 (Col-3), which are primary 
contributors to collagen deposition, was consistent with 
that of Sirius Red staining (Additional file 1: Figure S4B, 
C, D, E). Also, periodic acid-Schiff (PAS)-staining of liver 
sections revealed that MSC treatment improved glycogen 
synthesis and storage (Fig. 2c, h). Moreover, control liver 
sections around sinus hepaticus were significantly positive 
for α-smooth muscle actin (α-SMA), a marker of activated 
HSCs, whereas MSC-treated liver sections showed a size-
able reduction in α-SMA positivity (Fig. 2d, i).
Microscopic evaluation of HE-stained liver sections 
revealed massive inflammatory infiltration, particularly 
F4/80-positive macrophages, in livers from control mice. 
By contrast, MSC treatment markedly down-regulated 
F4/80-positive macrophage infiltration (Fig.  2b, e, g, j). 
Taken together, these results demonstrate that MSC 
therapy suppresses liver fibrosis by down-regulating 
macrophage infiltration and promoting HSC apoptosis or 
decreasing the activated HSCs.
MSCs inhibit hepatocellular apoptosis and enhance liver 
regeneration in vivo
To determine whether MSCs treatment reduces hepato-
cellular apoptosis, we examined TUNEL-reactive hepat-
ocyte nuclei in liver sections. In control mice with FHF 
and chronic liver fibrosis, many large apoptotic hepato-
cyte nuclei were observed, yet only few such nuclei 
were observed after MSC treatment. Furthermore, the 
extravasated blood observed after TAA stimulation dis-
appeared after MSC infusion (Fig. 3a, b). Quantification 
of these observations confirmed a dramatic reduction in 
TUNEL-positivity in MSC-treated mice with FHF and 
chronic liver fibrosis (0.10 ±  0.06 or 0.40 ±  0.05  % per 
field of view, respectively) compared with control mice 
(1.92 ± 0.40 or 2.83 ± 0.30 % per field of view) (Fig. 3e, f ), 
demonstrating that MSC effectively inhibits hepatocellu-
lar death in models of liver failure.
The therapeutic effects of MSCs may rely on the launch 
of endogenous repair programs. Hepatocytes positive for 
the proliferation marker Ki67 were quantified in mice 
with FHF and chronic liver fibrosis and compared with 
those in control mice (Fig.  3c, d). Whereas few Ki67-
positive hepatocytes were observed in control livers 
(0.08  ±  0.04 or 0.20  ±  0.03  % per field of view), many 
were observed in MSC–treated liver (2.62  ±  0.50 or 
1.62 ± 0.20 % per field of view) (Fig. 3g, h). These findings 
demonstrate that MSC treatment inhibits hepatocellular 
apoptosis and stimulates liver regeneration programs in 
mice with liver failure.
MSC‑CM partially ameliorates FHF, but dramatically 
improves chronic liver fibrosis
MSCs naturally support hematopoiesis by secreting 
several trophic molecules, including soluble extracel-
lular matrix glycoproteins, chemokines, cytokines, and 
growth factors. To determine whether MSC-CM plays 
an important role in improving liver failure, MSC-CM 
was intravenously infused into mice with FHF or chronic 
liver fibrosis. Interestingly, the therapeutic effect of 
MSC-CM infusion was similar to that of MSC infusion, 
although there were notable differences in their courses 
of action for FHF. Mice with FHF were sacrificed 24, 
48, or 72  h after MSC-CM infusion (Fig.  4a). Six of the 
eight survival control livers were soft and shrunken with 
extensive extravasated blood. Microscopic evaluation of 
HE-stained control liver sections consistently revealed 
massive hepatocellular death with cytoplasmic vacuoli-
zation, hemorrhage and inflammatory infiltration. These 
severe pathological changes were also observed in MSC-
CM-treated livers 24 and 48  h after infusion, although 
a therapeutic effect was observed 72  h after MSC-CM 
infusion (Fig. 4d, j, k). However, MSC-CM treatment did 
not significantly improve survival rate (55.6 % for MSC-
CM-treated vs. 44.5 % for control group) (Fig. 4c). There-
fore, it is likely that MSC-CM enhances the liver repair 
system only at later stages of self-recovery.
To access recovery from chronic liver fibrosis, six of 
normal, control and MSC-CM groups were sacrificed for 
various microscopic evaluations 3 weeks after MSC-CM 
infusion (Fig.  4b). Sirius Red-staining, HE-staining and 
α-SMA immunofluoresence-staining of liver sections 
revealed that MSC-CM treatment suppressed collagen 
fiber deposition, inhibited inflammatory infiltration, and 
promoted activated HSC apoptosis (Fig. 4e–g, l–n). Also, 
MSC-CM-treated livers exhibited less TUNEL-positivity 
and more Ki67-positive hepatocyte nuclei, indicating that 
MSC-CM trophic molecules inhibit hepatocyte apoptosis 
and enhance liver regeneration (Fig. 4h, i, o, p). Overall, 
these results show that MSC-CM improves chronic liver 
fibrosis, but only partially improves FHF.
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MSCs promote macrophage line RAW264.7 apoptosis 
and MSC‑CM promotes apoptosis and inhibits proliferation 
of HSC line LX‑2
Macrophages and HSCs have important role in the 
pathogenesis of FHF and chronic liver fibrosis, respec-
tively. To determine whether MSCs down-regulate 
macrophages and HSCs apoptosis in  vivo via a direct 
effect of MSCs themselves or an indirect effect of MSC-
secreted soluble factors, we examined the effect of MSCs 
or MSC-CM on in  vitro apoptosis and proliferation of 
RAW264.7 or LX-2. After co-culture of RAW264.7 and 
MSCs for 48  h, a two-fold increase in apoptosis was 
Fig. 2 MSC treatment suppresses inflammatory infiltration and down-regulates activated HSCs, inhibiting fiber deposition in CCl4-induced chronic 
liver fibrosis. a Sirius Red, b HE, and c PAS staining of liver sections from control and MSC-treated mice. d α-SMA immunofluorescence staining of 
liver sections shows a down-regulation of activated HSCs. e F4/80 immunofluorescence staining of liver sections from normal, control and MSCs-
treated mice. f, g Fibrosis and necroinflammatory scores determined using the scoring system of Ishak [31]. h, i, j Quantification of PAS-positivity, 
α-SMA-positivity and F4/80-positivety. Data are shown as mean ± standard error of the mean of 10 random high-power fields per mouse. *P < 0.05; 
**P < 0.01; ***P < 0.001
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observed (16.6 ± 2.0 % co-culture group vs. 7.9 ± 1.2 % 
control group) (Fig. 5a, d), whereas MSCs and MSC-CM 
did not effect on the proliferation of RAW264.7, MSC-
CM did not promote RAW264.7 apoptosis.
After LX-2 was supplemented with 2  % MSC-CM in 
co-culture for 48  h, we observed a massive apoptosis 
of LX-2 (34.5 ±  5.0 in 2  % MSC-CM-treated group vs. 
8.3 ± 1.5 % control group). With 8 % MSC-CM, no sig-
nificant increase in LX-2 apoptosis was observed (Fig. 5c, 
e). Supplementation with 2 % MSC-CM also suppressed 
the proliferation of LX-2 (1.88  ±  0.02 in 2  % MSC-
CM group vs. 2.80 ±  0.06 % control group) (Fig. 5b, f ). 
Taken together, these results suggest that MSCs them-
selves directly facilitate macrophage apoptosis, whereas 
HSC apoptosis and inhibition of proliferation occur via 
MSC-CM.
MSCs and MSC‑CM have anti‑inflammatory effects on TAA‑ 
and CCl4‑stimulated splenocytes, respectively
We examined the subset distribution of CD4+ T lympho-
cytes in spleens from control, MSC-treated, and MSC-
CM-treated mice using flow cytometry. Based on our 
prior experience, we expected that the subset distribution 
of CD4+ T lymphocytes in spleens would not be altered 
by MSC-CM treatment of TAA-stimulate mice. However, 
MSC infusion down-regulated pro-inflammatory Type 
1 T helper (Th1) and Th17 cells (Fig.  6c, d; Additional 
file 1: Figure S5A, B) and up-regulated anti-inflammatory 
regulatory T (Treg) cells in mice with FHF (Fig. 6f; Addi-
tional file 1: Figure S5D), whereas the distribution of anti-
inflammatory Th2 cells- was not significantly changed 
(Fig. 6e; Additional file 1: Figure S5C). Consistently, the 
size of spleen in mice from MSC-CM treatment group 
Fig. 3 MSC delivery decreases apoptosis and enhances hepatocellular proliferation in mice with liver failure. Liver sections from a TAA-stimulated 
and b CCl4-stimulated mice were stained by TUNEL (dark brown nuclei, large for hepatocytes) and counterstained with methyl green (light blue). 
Ki67 immunofluorescence staining of liver sections from c TAA-stimulated and d CCl4-stimulated mice.Quantification of TUNEL-positivity in e 
TAA-stimulated and f CCl4-stimulated livers. Quantification of Ki67-positivity in g TAA-stimulated and h CCl4-stimulated livers. Data are shown as 
mean ± standard error of the mean of 10 random high-power fields per mouse. *P < 0.05; **P < 0.01; ***P < 0.001
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was smaller than control group mice, which indicates 
that mice from MSC-CM treatment group were under 
lower inflammatory state compared with control group 
(Fig. 6a, b). Therefore, MSCs directly exert immunosup-
pressive effects in mice with TAA-induced FHF.
By contrast, both MSC and MSC-CM treatment 
exerted immunosuppressive effects in CCl4-induced 
chronic liver fibrosis, although better therapeutic effects 
were observed after MSC-CM delivery. MSC-CM 
increased levels of Th2 and Treg cells (Fig. 7c, d, h, i), and 
reduced levels of Th17 cells (Fig. 7b, g), whereas levels of 
Th1 cells were unchanged (Fig. 6o, j). Moreover, the size 
of spleen from MSC-CM treatment mice was smaller 
than control mice (Fig. 7k, l). Comparatively, MSC treat-
ment did not affect Th17 and Treg cells and only slightly 
alters inflammatory state in mice with chronic liver fibro-
sis. Also, MSC and MSC-CM treatment substantially 
down-regulated macrophages in the spleen of mice with 
acute and chronic liver failure (Figs. 6g, 7e, j; Additional 
file 1: Figure S5E), consistent with effects observed in the 
liver. Therefore, in mice with CCl4-induced chronic liver 
fibrosis, immunosuppressive effects are mainly attributed 
Fig. 4 MSC-CM delivery ameliorates TAA-stimulated FHF and CCl4-stimulated liver fibrosis. a Schema depicting MSC-CM treatment for FHF. b 
Schema depicting MSC-CM treatment for chronic liver fibrosis. c Kaplan–Meier survival analysis of mice with TAA-induced FHF. d MSC-CM treat-
ment substantially improved the gross histopathological appearance of TAA-stimulated livers. e, f Fibrosis and necroinflammatory scores were 
determined using the scoring system of Ishak for CCl4-stimulated livers. Quantification of (g) α-SMA-, (h) Ki67-, and (i) TUNEL-positivity. j HE staining 
of liver sections from control and MSC-CM-treated TAA-stimulated livers. k Necroinflammatory scores determined by Necroinflammatory score 
system of Ishak in TAA-stimulated livers. l Sirius red, m HE, n α-SMA immunofluorescence, o Ki67 immunofluorecence, p TUNEL staining of liver sec-
tions from CCl4-stimulated all group. Data are shown as mean ± standard error of the mean of 10 random high-power fields per mouse.*P < 0.05; 
**P < 0.01; ***P < 0.001
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to MSC-CM. There results demonstrate that MSCs 
themselves exert immunosuppressive effects in mice 
with TAA-induced FHF, whereas MSC-CM underlies the 
immunosuppressive effects in mice with CCl4-induced 
chronic liver fibrosis.
Discussion
Several clinical and animal model-based trials show 
promising and desirable therapeutic effects of MSCs in 
ameliorating FHF, chronic liver fibrosis, and even cir-
rhosis [15]. Recent investigations focusing on MSC-CM 
reveal several therapeutic mechanisms of MSCs treat-
ment [16]. However, which mechanism of action has a 
leading role in improving FHF or chronic liver fibrosis is 
inconclusive, even though this information is important 
for future researches. In the present study, we system-
atically investigated the effects of MSCs and MSC-CM 
treatment in mouse models of TAA-induced FHF and 
CCl4-induced chronic liver fibrosis in terms of enhanc-
ing liver regeneration, reducing hepatocellular apopto-
sis, down-regulating macrophage infiltration, altering 
the CD4+ T system into an anti-inflammatory state and 
promoting HSC apoptosis and inhibition of proliferation 
(Fig. 8).
We found that MSC and MSC-CM infusion simi-
larly stimulated liver regeneration and suppressed 
Fig. 5 MSCs promote RAW264.7 apoptosis, and low concentration of MSC-CM facilitates LX-2 apoptosis and inhibition of proliferation. a Co-culture 
of RAW264.7 and MSCs induced massive apoptosis of RAW264.7 48 h later, shown using a fluorescent live/dead assay. b A low concentration of 
MSC-CM suppressed LX-2 proliferation 48 h later. c A low concentration of MSC-CM increased LX-2 apoptosis 48 h later, shown using a fluorescent 
live/dead assay. d Percentage of apoptosis for co-culture and RAW264.7-alone conditions. e Percentage of apoptosis for co-culture and LX-
2-alone conditions. f Division index analysis of co-culture and LX-2-alone conditions. Experiments were performed in triplicate. Data are shown as 
mean ± standard deviation. *P < 0.05; **P < 0.01; ***P < 0.001
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hepatocelluar death in mice with acute and chronic 
liver failure. These results are consistent with a previous 
report that low-concentrations MSC-CM are sufficient 
to promote hepatocelluar proliferation and inhibition 
of hepatocyte apoptosis [14]. Higher concentrations 
of MSC-CM, however, did not confer better therapeu-
tic effect, most likely because MSC-CM includes small 
amounts of inhibitory components, such as TNF-α and 
TGF-β, whose negative effects at higher concentrations 
offset the therapeutic effects of trophic factors.
Another characteristic in common between MSC and 
MSC-CM therapy is the substantial reduction of mac-
rophages in the liver and spleen. Several studies show 
that distinct mechanisms of MSCs are responsible for the 
down-regulation of pro-inflammatory macrophages. For 
example, MSCs mediate a switch from pro-inflammatory 
M1-type macrophages to anti-inflammatory M2-type 
macrophages [17, 18]. Also, another study shows that 
MSC-CM suppresses M1-type macrophages in mice 
with endotoxin-induced acute lung injury [19]. However, 
co-culture of MSC-CM with RAW264.7 did not induce 
apoptosis of RAW264.7 in the present study, which could 
be partly attributed to functional differences among MSC 
populations that possess different spectrums of secreted 
factors [20].
Immunosuppression is an important therapeutic mech-
anism of MSCs in various models of autoimmune disease 
[21], and this is also true of MSC-CM [22, 23]. The pre-
sent study further demonstrates the immunosuppressive 
effect of MSC treatment, converting the body into an 
anti-inflammatory state by up-regulating anti-inflam-
matory Treg cells and reducing pro-inflammatory Th1 
and Th17 cells in TAA-induced FHF and CCl4-induced 
chronic liver fibrosis (Figs.  6, 7), which could partially 
explain the beneficial effects of MSC. MSC-CM delivery 
also led to an immunosuppressive response in chronic 
liver fibrosis, although immunosuppressive effects of 
MSC-CM treatment were not observed in mice with 
TAA-induced FHF. Therefore, we infer that MSCs them-
selves exert immunosuppressive effects in TAA-induced 
FHF, whereas MSC-secreted soluble factors dominate 
the immunosuppressive effects of MSC treatment in 
CCl4-induced chronic liver fibrosis. Moreover, the estab-
lishment of an anti-inflammatory state after MSC or 
MSC-CM treatment could occur indirectly via the up-
regulation of M2-type macrophages, which secrete vari-
ous anti-inflammatory factors such as CCL-1 and IL-10 
that up-regulate Th2 and Treg cells [24].
The principal mediators of hepatic fibrosis are HSCs, 
which substantially proliferate and produce vari-
ous extracellular matrices during the pathogenesis of 
liver fibrosis. Both MSC and MSC-CM treatment dra-
matically reduced activated HSCs-myofibroblasts. The 
down-regulation of activated HSCs may be achieved by 
different pathways. For example, fibrous scar-produced 
myofibroblasts can revert into inactive phenotypes [25]. 
Alternatively, the massive apoptosis and inhibition of 
proliferation of LX-2 that we observed during co-culture 
Fig. 6 MSC and MSC-CM down-regulate macrophages and converts the CD4+ T lymphocyte system into an anti-inflammatory state in TAA-stim-
ulated spleens. a Spleens from control and MSC-treated TAA-stimulated mice 72 h after MSC treatment. b Spleen weight in MSC-treated mice with 
FHF. Quantification of (c) Th1, (d) Th17, (e) Th2, (f) Treg and (g) macrophages in spleen
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of MSC-CM and LX-2 may be explained by a previously 
reported immunomodulatory mechanism [26]. However, 
the therapeutic effect of MSCs treatment has been called 
into question [27], with recent studies showing that MSC 
infusion can accelerate the progress of fibrosis via the 
conversion of MSCs into fibrous scar-produced myofi-
broblasts [28–30]. Therefore, the therapeutic effect of 
MSC infusion may be mainly realized by the actions of 
MSC-secreted factors that mediate the massive apoptosis 
of HSCs based on our results in vivo and LX-2 coculture 
with MSC-CM in vitro, thereby counteracting the nega-
tive effects of MSC-derived myofibroblasts.
Both MSC and MSC-CM therapy improved TAA-
induced FHF and CCl4-induced chronic fibrosis by acting 
on hepatocytes, macrophages, CD4+ T lymphocytes, and 
HSCs. However, the primary therapeutic mechanisms of 
MSC therapy differ between these two models of liver fail-
ure. MSCs can achieve healing of injury by two different 
Fig. 7 MSC and MSC-CM down-regulate macrophages and converts the CD4+ T lymphocyte system into an anti-inflammatory state in CCl4-stimu-
lated spleens. Both MSC and MSC-CM treatment had no significant effect on (a) Th1. A significant reduction of (b) Th17 was observed 3 weeks after 
MSC-CM but not MSC treatment. However, (c) an increase in Th2 and (e) a reduction in macrophages was observed after both MSC and MSC-CM 
treatment. MSC-CM but not MSC treatment up-regulated (d) Treg. Quantification of (f) Th1, (g) Th17, (h) Th2, (i) Treg, and (j) macrophages in the 
spleen. k Spleen weight in MSC-CM-treated mice with chronic liver fibrosis. l Spleens from control and MSC-CM-treated CCl4-stimulated mice
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modes—direct interaction with various target cells or 
secretion of various soluble molecules. For TAA-stimu-
lated FHF, MSC but not MSC-CM significantly amelio-
rated injury by promoting hepatocelluar proliferation and 
inhibiting hepatocyte apoptosis, suppressing macrophage 
infiltration, and converting the CD4+ T lymphocyte sys-
tem into an anti-inflammatory state. MSC-CM also stim-
ulated liver regeneration and inflammatory infiltration 
72 h after delivery. However, because the death of TAA-
stimulated mice generally occurred during the first 48  h 
after TAA injection, MSC-CM infusion did not decrease 
mortality rates during this early time period (44.4 % in the 
MSC-CM-treated group vs. 55.5 %in the control group). 
Therefore, MSCs themselves play the predominant ther-
apeutic role in MSC therapy for FHF. Several previous 
studies demonstrate extensive interactions between MSCs 
and various immune cells such as activated T cells. Immu-
nosuppressive outcomes from the interplay between 
MSCs and various immune cells may be the main mecha-
nism by which MSC infusion prevents the death of mice 
during the first 48 h after TAA injection. By contrast, for 
CCl4-stimulated chronic liver fibrosis, MSC-CM plays 
a predominant therapeutic role by enhancing the liver 
repair system, inhibiting inflammatory infiltration, and 
promoting the apoptosis of HSCs, which outweighs the 
negative effects of MSC-derived myofibroblasts. There-
fore, MSC-secreted soluble factors are the primary route 
of action during MSC therapy for CCl4-induced fibrosis.
Conclusion
In conclusion, we found that both MSCs and MSC-
CM induce integrated therapeutic effects on mice with 
liver failure, although the two treatments differ in their 
dominant therapeutic modes. In term of MSCs ther-
apy, our findings provide the clinical doctor with advis-
able remedies that MSC treatment is more suitable for 
FHF, whereas delivery of MSC-CM is more suitable for 
chronic liver fibrosis.
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